Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563433 · ClinicalTrials.gov registry record · Phase 3
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
A Phase 3 study, sponsored by Abeona Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 342
- Enrollment target
NCT00563433 is a Phase 3 study that has completed, run by Abeona Therapeutics. The registered enrollment target is 342 participants.
The verdict
NCT00563433, a Phase 3 study, has completed, sponsored by Abeona Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 342 participants
- Enrollment target
Study Summary
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
Interventions
- DRUG ofloxacin
- DRUG MSI-78
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 1994-08 |
| Est. Completion | 1996-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563433
The ClinicalTrials.gov registry entry for NCT00563433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abeona Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ofloxacin is the first listed.
NCT00563433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563433 about?
NCT00563433 is a clinical study titled "MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers". 224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
What is the current status of trial NCT00563433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 342 participants. The study started on 1994-08. Estimated completion is 1996-07.
What interventions are being tested in trial NCT00563433?
The interventions under investigation include: ofloxacin (DRUG), MSI-78 (DRUG).
Who is sponsoring clinical trial NCT00563433?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.